March 27, 2025 | By Richard Weisner

Facebook
X
LinkedIn

Ivermectin’s Path to OTC Status: A Game-Changer in the Making

In a groundbreaking shift, whispers in the pharmaceutical world suggest that ivermectin, the long-celebrated antiparasitic drug, may soon be headed for over-the-counter (OTC) approval in various markets. Known for its efficacy against a range of parasites, ivermectin has been a prescription-only medication for decades, reserved for conditions like river blindness, strongyloidiasis, and even topical use for head lice and rosacea. However, as regulatory bodies and public health advocates reassess its safety profile and widespread utility, the potential for OTC availability could open a lucrative door for forward-thinking companies. Here’s how one could jump ahead of the curve, why the market is ripe for this move, and how parasites—more common than most realize—make this a potential goldmine, especially for a company like Green Stars Labs with expertise in capsule formulations.

 

Ivermectin's Path to OTC Status

The Push for OTC Ivermectin

Ivermectin’s journey from a veterinary breakthrough to a human health staple has been remarkable. Discovered in the 1970s and approved for human use in 1987, it earned its discoverers a Nobel Prize in 2015 for combating parasitic diseases that plague millions globally. Today, its safety record—bolstered by decades of use at prescribed doses—has sparked discussions about broadening access. While the U.S. FDA currently approves ivermectin only by prescription for specific parasitic infections, other regions, like parts of Latin America and Southeast Asia, have already loosened restrictions amid growing demand. The OTC version of ivermectin lotion (Sklice) for head lice in the U.S. hints at what’s possible: a safe, consumer-friendly formulation that doesn’t require a doctor’s visit.

The case for OTC status is compelling. Ivermectin’s side effects at approved doses are minimal, and its broad-spectrum action against parasites makes it a versatile tool. As public awareness grows—fueled by its controversial spotlight during the COVID-19 pandemic, despite lacking approval for that use—consumers are increasingly seeking it out. Regulatory bodies may soon bow to this pressure, especially for low-dose formulations targeting common parasitic infections. Companies that anticipate this shift can position themselves as market leaders.

Jumping Ahead of the Curve

To capitalize on ivermectin’s potential OTC approval, a proactive approach is key. Here’s how a company could get ahead:

  1. Develop a Consumer-Friendly Product: Focus on a low-dose capsule tailored for common parasites like pinworms or head lice, which don’t always warrant a doctor’s visit. Clear labeling, precise dosing instructions, and a safety-first design will be critical to gain regulatory and consumer trust.
  2. Secure Supply Chains: Ivermectin’s active ingredient is widely available from generic manufacturers, but locking in reliable suppliers now ensures production scalability once approval hits. Partnering with API (active pharmaceutical ingredient) producers in India or China, where costs are competitive, could keep margins healthy.
  3. Navigate Regulatory Pathways: Engage with health authorities early—think FDA meetings or equivalent in target markets—to align on OTC requirements. Pilot studies demonstrating safety and efficacy in self-administered settings could accelerate approval.
  4. Build Brand Awareness: Launch educational campaigns highlighting ivermectin’s benefits for everyday parasitic infections. Position it as a household essential, much like antacids or pain relievers, to normalize its OTC presence.

For a company like Green Stars Labs, with a core competency in capsule formulations, this is a natural fit. Their expertise in crafting high-quality, bioavailable capsules could set their ivermectin product apart, ensuring rapid absorption and consumer satisfaction—key factors in a crowded OTC market.

The Market: Parasites Are Everywhere

Parasites aren’t just a third-world problem—they’re more common than most realize, even in developed nations. Pinworms, for instance, infect up to 50% of children in some U.S. communities, spread through poor hygiene or contaminated surfaces. Head lice affect 6-12 million kids annually in the U.S. alone, driving parents to seek quick, accessible solutions. Globally, soil-transmitted helminths (like roundworms and hookworms) afflict over a billion people, while scabies—an itchy mite infestation—spikes in crowded settings like schools and nursing homes. These aren’t rare diseases; they’re everyday nuisances that OTC ivermectin could tackle head-on.

The market potential is massive. In the U.S., the OTC antiparasitic segment is underdeveloped compared to other categories like allergy meds or painkillers, yet demand is latent. Globally, emerging markets in Africa, Asia, and Latin America—where parasitic infections are endemic—represent untapped billions. A single-dose ivermectin capsule, priced affordably (say, $5-$10 OTC), could rival the convenience of lice shampoos or deworming syrups, capturing both individual and institutional buyers (schools, camps, shelters).

Why It’s a Money Maker

An OTC ivermectin capsule is a money maker for several reasons:

  • High Volume, Low Cost: Parasitic infections are recurrent, driving repeat purchases. With generic ivermectin’s low production cost (pennies per dose in bulk), profit margins could soar, especially at OTC price points.
  • Underserved Niche: Few OTC options exist for internal parasites like pinworms—most treatments require prescriptions or are less effective home remedies. Ivermectin fills this gap with proven efficacy.
  • Scalability: Once approved in one market, the model can expand globally, leveraging Green Stars Labs’ capsule expertise to tailor formulations (e.g., pediatric doses or combo therapies).
  • Consumer Empowerment: OTC status shifts control to the consumer, bypassing healthcare gatekeepers. This aligns with trends toward self-care, amplified by pandemic-era skepticism of centralized medical authority.

Green Star Labs: The Capsule Advantage

Green Stars Labs is uniquely positioned to dominate this space. Their mastery of capsule formulations—optimizing stability, bioavailability, and shelf life—gives them an edge over competitors fumbling with tablets or liquids. A sleek, easy-to-swallow ivermectin capsule could become the go-to choice for parents, travelers, and health-conscious adults alike. Add in sustainable packaging or a pediatric-friendly version, and they’ve got a product that screams innovation.

Let’s Get Started Today!

If an OTC Ivermectin capsule formulation featured in this article is a good fit for your wellness brand, request a quote now to take the first step to making your vision a reality.

Request A Quote

Request A Quote

Richard Weisner

About Richard Weisner

My goal is to help businesses scale and succeed by offering personalized support, industry knowledge, and access to cutting-edge manufacturing technology. Let’s connect and explore how we can collaborate to bring your product ideas to life!

Get In Touch  |  Connect on LinkedIn

Recent Posts

FDA Disclaimer: Content published in our Nutraceutical Market Trends blog is for educational purposes and is not intended to represent medical advice. Our audience is B2B brand owners and customers who are interested in developing innovative nutraceutical products. Content that may indicate specific health claims for ingredients or delivery systems has not been evaluated by the FDA. Dietary supplement products manufactured by Green Star Labs, Inc. are not intended to diagnose, treat, cure or prevent any disease.

Green Star Labsoratories, Inc

Green Star Labs Equipment and Capabilites

custom gummies manufacturing

Gummy Full-Scale Starchless Manufacturing

  • Pectin Based – Vegan, Sugar and Sugar-Free custom formulations
  • Standard 4.5g Squares and Custom Molds
  • Multiple production lines – 100,000 to 500,000 Pieces per Shift @ 4.5g
  • Examples: Lion’s Mane/Cordyceps Focus Gummies, Melatonin-less Sleep Gummies, CBD Relax and Revive Gummies, Apple Cider Vinegar Gut Health Gummies, Ashwagandha Adaptogen Gummies, Sugar-Free Creatine Gummy

Small-Scale Gummy R&D

  • Testing the Market, Developing Flavor Profiles, Troubleshooting and problem solving product challenges.
  • Examples: Developing SOP and Formulations for Creatine Gummies, Flavor Masking Caffeine and Cannabinoids

Gummy Co-Packing

  • 5 – 150ct Pouches Packaged in-line – Up to 14,000 pouches per shift @ 5ct .
  • 20 – 90ct Bottles Packaged in-line – Up to 8000 bottles per shift @ 30ct .
  • Examples: 5 and 20ct Snoop Pouches, 30ct Top Fungi Jars, 60ct Fndmntl ACV Jars, 120ct Novos Pouches.

Capsule Full-Scale Starchless Manufacturing

  • Tooling for Size 1, 0, 00 shells (HPMC Standard)
  • Multiple Encapsulators – 60,000 to 1.1M per shift
  • Examples: NAD+ Precursor Supplements, Joint Health, Curcumin and Herbal Blends

Small-Scale Capsule R&D

  • Piloting and Running Trials for efficacy or product performance

Tablet Full-Scale Manufacturing

  •  Tooling for 10mm, 14mm, 16mm, 26mm Diameter Punches
  • 24 Station Press – up to 900,000 per shift
  • Examples: Probiotic Tablets, Chewable herbal remedies, Calcium and mineral blends

Solid Dosage Co-Packing

  • 10ct Blisters formed and sealed – then packaged in-line
  • 15 – 120ct Bottles Packaged in-line – up to 20,000 per shift

Ingestible Liquid Blending

  • Low-Volume Blending through 1800L+ Batches

Bulk Liquid Co-Packing

  • Packed into drums or pails upon request

RTD Shot Bottle Filling

  • 2oz Cosmo Round Bottles @ ~ 10,000 – 15,000 units per shift pending full shrink
  • Manufacturing Lines to Support Flexible Load Balance

RTD Beverage Bottle Filling

  • 8, 12, 16oz and Greater Bottles @ ~ 10,000 units per shift pending full shrink

Topical Cosmetic Blending

  • 50L batch size for High-Viscosity Products: Creams, Gels, Masks
  • 200L batch size for Low-Viscosity Products: Oils, Serums, Treatments

Bulk Cosmetic Co-Packing

  • Packed into drums or pails upon request

Lotion Tube Filling

  • Tooling available for 15ml (0.5oz) – 120ml (4oz) Lotion Tubes
  • Variable Material Specifications
  • Max Through-put 205 tubes/minute

Cosmetic Liquid Sachet Filling

  • Liquid Sachets > 10g minimum sizing
  • Max Through-put 20 sachets/minute

Cosmetic Bottle Co-Packing

  • Variable characteristics and packaging specs acceptable
  • Jars, Bottles, Airless Pumps, Plastic, Glass, Heat Induction Seal

 

 

Free-Flowing Powder Blending

  • Low-Volume Blending through 350kg+ Batches
  • Handles Herbals/Botanicals as well as mixed particle sizes

Large Scale Bulk Powder Co-Packing

  • Packed from 10kg+ bags into boxes

Medium Scale Powder Filling

  • 100g+ – 1kg Pouches and Cannisters

Single-Serving Sachet Filling

  • Single Lane FFS machine auger fed powder blends
  • 10+/minute run speed @ 30g sachets

 

Home  |  About Green Star Labs  |  Our Expertise  |  Certifications |  Our Team  |  Contact Us

© Copyright 2025 Green Star Labs, Inc. All rights reserved.